2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Checkpoint Inhibitor, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, Translational Research, MPN, CML, CMML, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly, Animal Model
PAPER

5487 Mitochondrial membrane potential identifies potent and malignant JAK2V617F blood-forming stem cells with distinct properties and therapy response

Jiajing Qiu, PhD, Mary Slavinsky, N/A2, Alan Shih, MD3, Saghi Ghaffari Jr, MD PhD4
1 Icahn School of Medicine at Mount Sinai, New York, New York, United States
2 Icahn School of Medicine at Mount Sinai, New York, New York, United States
3 Icahn School of Medicine at Mount Sinai, New York, New York, United States
4 Icahn School of Medicine at Mount Sinai, New York, New York, United States

Myeloproliferative neoplasms (MPNs) are clonal hematopoietic malignancies initiated in hematopoietic stem cells (HSCs). Despite their success, current therapies using JAK inhibitor (Ruxolitinib and related therapies) or IFN-alpha are limited in their efficacy. In addition, the exact target population and the effects on malignant blood-forming stem cells (SCs) remains poorly understood.

To address this challenge, we leveraged a mitochondrial membrane potential (MMP)-based approach that we and others have devised  –  MMP is overall coupled to mitochondrial activity –  to select for quiescent and potent malignant blood forming stem cells (SCs) and study their response to therapy in a JAK2V617F conditional knock-in mouse model of polycythemia vera (PV) (JAK2VF SCs; Lineage- Sca+cKit+CD48-CD150+). We found that JAK2VF SCs are highly heterogeneous in their MMP profile and exhibit an overall higher level of MMP relative to wide type (WT) HSCs. MMP-low and -high JAK2VF SC subsets – as defined by JAK2VF SC populations within 25% lowest and highest MMP –  were clearly segregated.  While 40% of MMP-high JAK2VF SCs from fresh bone marrow are actively in cell cycle, over 90% of MMP-low JAK2VF SCs remain quiescent (G0). Consistent with these findings, 70% of MMP-high JAK2VF SCs divided at least once within 36 hours in a single cell division assay as compared to less than 10% of MMP-low JAK2VF SCs. Regardless of MMP levels and as anticipated, MMP-low or -high JAK2VF SCs divided more often than their WT counterparts. As observed in healthy MMP-low (quiescent) HSCs, MMP-low (quiescent) JAK2VF SCs – in contrast to their MMP-high (activated) counterparts – featured greatly fragmented mitochondrial networks and abundant, large lysosomes. MMP-low JAK2VF SCs generated two-fold more long-term culture initiating cells (LTC-ICs)-derived colonies relative to MMP-high JAK2VF SCs ex vivo. Remarkably, MMP-low but not -high JAK2VF SCs demonstrated long-term (LT) competitive repopulation capacity in lethally irradiated recipient mice for over 16 weeks and self-renewal capacity in a secondary transplantation. In contrast, the ability of MMP-high JAK2VF SCs to produce blood in recipient mice declined rapidly within 8 weeks post transplantation. These findings suggest that MMP-low JAK2VF SCs are relatively enriched for functional malignant stem cells. Next, we interrogated the effect of JAK inhibitor Ruxolitinib – a standard, though non curative, MPN therapy – on MMP-subsets of JAK2VF SCs. Despite reducing JAK2VF SC proliferation, Ruxolitinib treatment ex vivo increased the number of LTC-ICs-derived colonies. We then treated JAK2VF mice with Ruxolitinib (90mg/kg twice daily) for 2 weeks, which reduced both JAK2VF SC total number and BM frequency. The hyper-fused mitochondrial networks – that indicate mitochondrial stress – in MMP-high JAK2VF subsets and overall MMP level were also decreased after treatment. To further evaluate the effect of this treatment on JAK2VF SCs’ function, MMP-low and -high JAK2VF SCs were isolated from Ruxolitinib-treated mice and interrogated for their in vivo competitive repopulation ability in a transplantation setting. Surprisingly, a two-week Ruxolitinib treatment did not ablate LT-repopulating MMP -low JAK2VF SCs or impair their self-renewal capacity, though donor chimerism was reduced two-fold in a secondary transplantation.  In contrast, a two-week in vivo IFN-alpha 4 treatment of JAK2VF mice significantly reduced repopulating MMP-low SCs within 4 weeks. Thus, JAK2 inhibitor reduces the frequency of activated malignant stem cells without eliminating long lasting quiescent cells. In contrast IFN-alpha eliminated both MMP -low and -high JAK2VF SCs in our experimental settings.

These results identify MMP-low subsets of JAK2VF malignant SCs as being enriched for quiescent, highly potent stem cells, whereas the MMP-high JAK2VF SC fraction is characterized by high proliferative activity and a greater propensity for exhaustion. Furthermore, our findings reveal substantial functional and therapeutic heterogeneity within the JAK2VF stem cell compartment, demonstrating that MMP-low JAK2VF malignant stem cell subsets are relatively resistant to Ruxolitinib but remain responsive to IFN-alpha. Collectively, these findings suggest that MMP expression may serve as a marker to prospectively identify highly potent, quiescent malignant stem cells and to evaluate their therapeutic responses within heterogeneous malignant cell populations.
Jiajing Qiu, PhD: No relevant conflicts of interest to declare.